The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.
6 reports, 3 independent
Updated Aug 13
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
-
Sage Therapeutics (United States)
company in Cambridge, Massachusetts, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- StockStorySUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’
- StockStoryWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 14.4% in the afternoon session after the company
- GlobeNewswireSupernus Announces Second Quarter 2025 Financial Results Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million
- GuruFocus.comSupernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the
- GlobeNewswireSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE®
- Unknown outlet